Skip to content
sellWeak cluster of 5

Peter Rahmer sold $37k of RLAY

See remarks at Relay Therapeutics, Inc.. 12,103 shares at an average of $3.02, traded Apr 28, 2025, filed Apr 30, 2025.

Warning score
36
Value
$37k
12,103 shares
Holdings after
390,081
-3% from before
From 52-week low
+63%
low $2.00, close $3.26
From 52-week high
-60%
high $8.11, as of Apr 28, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $37k at market
    +6
  • Share of holdings sold
    Sold 3.0% of holdings
    0
  • Cluster
    5 insiders selling within 14 days
    +15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

RLAYOct 9, 2026 · close 17.88
Since filing Apr 30, 2025: +436.9%SPY +42.7% · excess +394.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000950170-25-061367, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Apr 28, 2025SOpen-market sale
Common Stock
-1,364$3.17$4,324400,820Apr 30, 2025
Apr 30, 2025SOpen-market sale
Common Stock
-10,739$3.00$32k390,081Apr 30, 2025

Related signals

Other insiders at Relay Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
RLAYsell 210b5-1
Relay Therapeutics, Inc.
Thomas Catinazzo
Chief Financial Officer
$329k
17,717 shares
-14%
36Weak
RLAYsell 210b5-1
Relay Therapeutics, Inc.
Sanjiv Patel
President and CEO
$872k
48,199 shares
-9%
26Weak
RLAYsell 310b5-1
Relay Therapeutics, Inc.
Donald A Bergstrom
President, R&D
$162k
8,530 shares
-2%
37Weak
RLAYsell 310b5-1
Relay Therapeutics, Inc.
Thomas Catinazzo
Chief Financial Officer
$336k
17,717 shares
-13%
44Moderate
RLAYsell 310b5-1
Relay Therapeutics, Inc.
Sanjiv Patel
President and CEO
$913k
48,199 shares
-8%
14Weak
RLAYsell10b5-1
Relay Therapeutics, Inc.
Thomas Catinazzo
Chief Financial Officer
$178k
17,717 shares
-7%
39Weak
RLAYsell 2
Relay Therapeutics, Inc.
Donald A Bergstrom
President, R&D
$167k
21,581 shares
-5%
40Moderate
RLAYsell 2
Relay Therapeutics, Inc.
Thomas Catinazzo
Chief Financial Officer
$120k
15,515 shares
-6%
57Moderate
RLAYsell 4
Relay Therapeutics, Inc.
Sanjiv Patel
President and CEO
$435k
62,073 shares
-8%
48Moderate
RLAYsell 4
Relay Therapeutics, Inc.
Donald A Bergstrom
President, R&D
$225k
30,897 shares
-6%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Peter Rahmer sold $37k of RLAY | InsiderTell